Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06036225
Other study ID # 21081JB-AS
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 24, 2022
Est. completion date September 27, 2024

Study information

Verified date December 2023
Source Belfast Health and Social Care Trust
Contact Suzanne Lester, PhD
Phone 07825515905
Email slester01@qub.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a study developing a prehabilitation intervention and then testing the acceptability and feasibility of the intervention. Start date Aug 2022 for Focus groups and Feb 2023 Co-design workshops and feasibility study date pending


Description:

This study is using focus groups and experience based co-design workshops to co-design a remote multicomponent prehabilitation intervention for patients awaiting liver transplantation. Once the intervention is developed it will then be tested for acceptability and feasibility with the liver transplantation cohort in Belfast Northern Ireland.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date September 27, 2024
Est. primary completion date July 24, 2024
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - on the transplant waiting list - grade 3 below for encephalopathy Exclusion Criteria: - grade 4 above encephalopathy - Known adverse reaction to exercise - New stroke - lacks capacity to consent

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Prehabilitation
Remote prehabilitation multi-component.

Locations

Country Name City State
United Kingdom Queen's University Belfast Belfast

Sponsors (2)

Lead Sponsor Collaborator
Belfast Health and Social Care Trust Queen's University, Belfast

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment It will be presented in percentage form and will be defined by
Number of participants active on the list.
Number of participants eligible to participate.
Number of participants informed about the iPRehab study.
Number of participants who were interested in participating.
Number of participants recruited.
Number of participants interested but didn't recruit and reasons why.
Number of participants who own a computer/phone/tablet.
Number of participants who can use a computer/phone/tablet independently.
Number of participants who need support to use a device. Detail the support required.
Min score 0% Max Score 100% Higher values indicate a higher recruitment rate.
6 months
Primary Adherence This will be recorded using percentage and will be defined by
Number of participants who attended 1:1 sessions.
Number of participants who attended the group exercise classes using a class log.
Number of participants who attend the online monthly peer support sessions while active on the liver transplantation waiting list.
Number of participants who accessed the website/web app.
Which sections of the website/web app are utilised and the number of participants who access each section.
Number of participants who wear the activity tracker and report weekly step count.
Min score 0% Max Score 100% Higher values indicate a higher adherence rate.
6 months
Primary Retention This will be recorded using percentage and will be defined by
Number of participants who completed the baseline assessment.
Number of participants who completed the 12-week iPRehab study.
Number of participants who completed the assessment 1 week post the iPRehab study.
Number of participants who completed the assessment 12 weeks post the iPRehab study.
Number of participants who drop out and the reasons
Min score 0% Max Score 100% Higher values indicate a higher retention rate.
6 months
Primary Acceptability This will be measured using an acceptability questionnaire.
Min score 0% Max Score 100% Higher values indicate a higher acceptability.
6 months
Secondary Physical function 6 minute walk test. This will be recorded in meters covered in the 6 minute duration of the test.
Min score 0 Max Score 1000
Higher values indicate better physical function.
6 months
Secondary Frailty The Liver frailty index. This index will determine the degree of frailty patients present while awaiting liver transplantation. This scale determines if the patients are frail, pre-frail or robust.
Min score 1 Max Score 7 Higher values indicate a higher degree of frailty.
6 months
See also
  Status Clinical Trial Phase
Completed NCT02798861 - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed NCT03527238 - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine Phase 2
Completed NCT01696331 - Text Messaging for Adherence in Adolescent Liver Transplant Recipients N/A
Recruiting NCT05051605 - Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
Recruiting NCT05940857 - Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
Completed NCT01598987 - Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. Phase 3
Active, not recruiting NCT05074160 - OCS Liver Perfusion (OLP) Post-Approval Registry
Completed NCT05087550 - Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation
Recruiting NCT04836923 - LIFT Intervention in Liver Transplant Candidates N/A
Not yet recruiting NCT03666689 - Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation
Not yet recruiting NCT06088758 - Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool N/A
Terminated NCT01230502 - Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation N/A
Completed NCT00171509 - Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients Phase 4
Not yet recruiting NCT06254248 - Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT06075745 - Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates Phase 2
Completed NCT02057484 - A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
Active, not recruiting NCT03577431 - Liver Transplantation With Tregs at MGH Phase 1/Phase 2
Recruiting NCT06342557 - Transitional ePRO Diary Liver
Not yet recruiting NCT04265157 - Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
Recruiting NCT02863250 - Australian and New Zealand Massive Transfusion Registry